ClinicalTrials.gg
RecruitingNCT06140524LINKER-MGUS1Updated Jul 8, 2026

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

A Phase 2 interventional study of Linvoseltamab in Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM), sponsored by Regeneron Pharmaceuticals. Recruiting at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance (HR-MGUS) and Non-High-Risk Smoldering Multiple Myeloma (NHR-SMM).

The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of HR-MGUS and NHR-SMM.

The study is looking at several other research questions, including:

  • How many participants treated with linvoseltamab have improvement of their HR-MGUS or NHR-SMM?
  • What side effects may happen from taking the study drug?
  • How much study drug is in the blood at different times?
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects).
02

Conditions studied

  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)

Keywords

  • linvoseltamab
  • monoclonal immunoglobulin (M-protein)
  • cancer interception
  • immunotherapy
  • plasma cell disorders
03

In context

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

This study's planned enrollment of 116 is above the median of 50 across 52 interventional studies indexed under Monoclonal Gammopathy of Undetermined Significance.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. HR-MGUS or NHR-SMM as defined in the protocol
  2. (ECOG) performance status ≤1
  3. Adequate hematologic and hepatic function, as described in the protocol
  4. Estimated (GFR) ≥30 mL/min/1.73 m\^2 by the Modification of Diet in Renal Disease (MDRD) equation

Key Exclusion Criteria:

  1. High-risk SMM, as defined in the protocol
  2. Evidence of any of myeloma-defining events, as described in the protocol
  3. Diagnosis of systemic light-chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), solitary plasmacytoma, or symptomatic MM
  4. cardiac or vascular disease within 3 months of study enrollment, as described in the protocol
  5. Any infection requiring hospitalization or treatment with intravenous (IV) anti-infectives within 28 days of the first dose of linvoseltamab
  6. Uncontrolled (HIV), Virus (HBV), or Virus (HCV) infection; or other uncontrolled infection or unexplained signs of infection, as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Safety Run-In (Part 1)

    Sequential groups of participants will be enrolled to assess the initial safety and tolerability of the step-up regimen leading up to the start of different full doses of linvoseltamab.

    Drug: Linvoseltamab

  • Experimental
    Expansion (Part 2) - Dose regimen 1

    Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens

    Drug: Linvoseltamab

  • Experimental
    Expansion (Part 2) - Dose regimen 2

    Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens

    Drug: Linvoseltamab

  • Experimental
    Expansion (Part 2) - Dose regimen 3

    Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens

    Drug: Linvoseltamab

  • Experimental
    Expansion (Part 2) - Dose regimen 4

    Participants will be randomized in a 1:1:1:1 ratio across 4 dosing regimens

    Drug: Linvoseltamab

Interventions

  • Administered per the protocol

    Also known as: REGN5458, Lynozyfic™

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events Interest (AEI) during the safety observation period

    Part 1 An AEI is a toxicity potentially related to study treatment that may preclude dose escalation or expansion according to the Bayesian Optimal Interval (BOIN) design decision rules

    Time frame: 35 days

  2. Frequency of Treatment-Emergent Adverse Event (TEAEs) during the safety observation period

    Part 1 As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: 35 days

  3. Severity of TEAEs during the safety observation period

    Part 1 As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: 35 days

  4. Achievement of Complete Response (CR) as determined by the investigator

    Part 2

    Time frame: Up to 5.5 years

Secondary outcomes

  1. Frequency of TEAEs

    As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: Up to 5.5 years

  2. Severity of TEAEs

    As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: Up to 5.5 years

  3. Frequency of Serious Adverse Events (SAEs)

    Time frame: Up to 5.5 years

  4. Severity of SAEs

    Time frame: Up to 5.5 years

  5. Frequency of laboratory abnormalities

    As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: Up to 5.5 years

  6. Severity of laboratory abnormalities

    As assessed by the NCI-CTCAE grading system version 5 (for all grades)

    Time frame: Up to 5.5 years

  7. Minimal Residual Disease (MRD) negativity among participants that achieve a response of CR

    Time frame: Up to 5.5 years

  8. Sustained MRD negativity on an annual basis

    Time frame: Up to 3 years after achievement of CR

  9. Overall response of Partial Response (PR) or better as determined by the investigator

    Time frame: Up to 5.5 years

  10. Duration Of Response (DOR) as determined by the investigator

    Time frame: Up to 5.5 years

  11. Biochemical Progression-Free Survival (PFS) as determined by the investigator

    Time frame: Up to 5.5 years

  12. Concentration of linvoseltamab in serum over time

    Time frame: Up to 9 months

  13. Incidence of Anti-Drug Antibodies (ADAs) to linvoseltamab over the study duration

    Time frame: Up to 5.5. years

  14. Magnitude of ADAs to linvoseltamab over the study duration

    Time frame: Up to 5.5. years

07

Study locations

39 of 39 sites recruiting
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Recruiting
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • University of Michigan Health
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • NYU Langone Health Perlmutter Cancer Center
    New York, New York 10016, United States
    Recruiting
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
    Recruiting
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • University of Washington
    Seattle, Washington 98109, United States
    Recruiting
  • Algemeen Ziekenhuis (AZ) Klina
    Brasschaat, Antwerpen 2930, Belgium
    Recruiting
  • AZ St.-Elisabeth Herentals vzw
    Herentals, Antwerp 2200, Belgium
    Recruiting
  • AZ Sint Maarten Algemeen Ziekenhuis Emmaus
    Mechelen, Flanders 2800, Belgium
    Recruiting
  • Algemeen Ziekenhuis St Jan Brugge Oostende Av
    Bruges, West-Vlaanderen 8000, Belgium
    Recruiting
  • Algemeen Ziekenhuis AZ Delta
    Roeselare, West-Vlaanderen 8800, Belgium
    Recruiting
  • Ziekenhuis Netwerk Antwerpen Cadix, Hematology
    Antwerp, 2030, Belgium
    Recruiting
  • Centre Hospitalier Universitaire De Poitiers
    Poitiers, New Aquitaine 86000, France
    Recruiting
  • Institut Curie
    Paris, Île-de-France Region 75005, France
    Recruiting
  • Galway University Hospital
    Galway, Connacht H91 YR71, Ireland
    Recruiting
  • Cork University Hospital
    Cork, T12 EC8P, Ireland
    Recruiting
  • Mater Misericordiae University Hospital
    Dublin, D07 R2WY, Ireland
    Recruiting
  • Istituto Romagnolo per lo Studio Dei Tumori Dino Amadori
    Meldola, Forli-Cesena 47014, Italy
    Recruiting
  • IRCCS Ospedale Policlinico San Martino
    Genoa, Genova 16132, Italy
    Recruiting
  • San Paolo Hospital
    Milan, Lombardy 20142, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria (AOU) SS. Antonio e Biagio e Cesare Arrigo
    Alessandria, Piedmont 15121, Italy
    Recruiting
  • UOC Ematologia e Terapia Cellulare - PO Mazzoni AST Ascoli Piceno
    Ascoli Piceno, 63100, Italy
    Recruiting
  • Universita degli Studi di Pavia - Fondazione IRCCS Policlini
    Pavia, 27100, Italy
    Recruiting
  • Ospedale Santa Maria delle Croci
    Ravenna, 48121, Italy
    Recruiting
  • Wojewodzki Szpital Zespolony - Ludwik Rydygier Provincial Hospital
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
    Recruiting
  • Specjalistyczny Szpital im A. Sokolowskiego w Walbrzychu
    Wałbrzych, Lower Silesian Voivodeship 58-309, Poland
    Recruiting
  • Pratia MCM Krakow
    Krakow, Malopolska 30-510, Poland
    Recruiting
  • University Clinical Center / Medical University of Gdansk
    Gdansk, Pomeranian Voivodeship 80-219, Poland
    Recruiting
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)
    Lodz, 93-513, Poland
    Recruiting
  • Swietokrzyskie Centrum Onkologii
    Kielce, Świętokrzyskie Voivodeship 25-734, Poland
    Recruiting
  • Hospital Universitario Virgen de las Nieves
    Granada, Andalusia 18014, Spain
    Recruiting
  • Hospital Universitari Mutua Terrassa
    Terrassa, Barcelona 08221, Spain
    Recruiting
  • Hospital Clinico Universitario Virgen De La Arrixaca
    El Palmar, Murcia 30120, Spain
    Recruiting
  • Hospital de Cabuenes
    Gijón, Principality of Asturias 33203, Spain
    Recruiting
  • Hospital Sant Pau
    Barcelona, 08041, Spain
    Recruiting
  • Institut Catala dOncologia (ICO Hospitalet)
    Barcelona, 08908, Spain
    Recruiting
  • Universitaru Hospital La Princesa
    Madrid, 28006, Spain
    Recruiting
  • Hospital General Universitario Morales Meseguer
    Murcia, 30008, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for May 2032, 92 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 20, 2023
StartActual
Sep 16, 2024
Primary completionEst.
May 18, 2032
CompletionEst.
May 18, 2032
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06140524
Responsible party
Sponsor
First posted
Nov 20, 2023
Start date
Sep 16, 2024
Primary completion
May 18, 2032 (estimated)
Completion
May 18, 2032 (estimated)
Last update
Jul 8, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linvoseltamab

Start the discussion